Gary J. Stelman

DEVELOPMENT OF AN IN VIVO PRECLINICAL SCREEN MODEL TO ESTIMATE ABSORPTION AND FIRST-PASS HEPATIC EXTRACTION OF XENOBIOTICS. II. USE OF KETOCONAZOLE TO IDENTIFY P-GLYCOPROTEIN/CYP3A-LIMITED BIOAVAILABILITY IN THE MONKEY

Keith W. Ward, Gary J. Stelman, Jayme A. Morgan et al. · Drug Metabolism and Disposition · 2004 · 43 citations

Pharmacy, Pharmacokinetics, Pharmacology +16

Preclinical Pharmacokinetics and Interspecies Scaling of a Novel Vitronectin Receptor Antagonist

Keith W. Ward, Leonard M. Azzarano, William E. Bondinell et al. · Drug Metabolism and Disposition · 1999 · 39 citations

Medicine, Pharmacokinetics, Pharmacology +17

Comparison of N,N′-diarylsquaramides and N,N′-diarylureas as antagonists of the CXCR2 chemokine receptor

Brent W. McCleland, Roderick S. Davis, Michael R. Palovich et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 37 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +12

The single and multiple dose pharmacokinetics of pranlukast in healthy volunteers

Dion R. Brocks, J Upward, Panayiotis Georgiou et al. · European Journal of Clinical Pharmacology · 1996 · 30 citations

Pharmacy, Pharmacokinetics, Pharmacology +8

Preclinical pharmacokinetics of SB-203580, a potent inhibitor of p38 mitogen-activated protein kinase

Katie Ward, J. W. Proksch, L. M. Azzarano et al. · Xenobiotica · 2001 · 23 citations

Medicine, Pharmacokinetics, Pharmacology +9